Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
Authors:
- Fumihiro OgawaFOFumihiro Ogawa
- Yasufumi OiYOYasufumi Oi
- Kento NakajimaKNKento Nakajima
- Reo MatsumuraRMReo Matsumura
- Tomoki NakagawaTNTomoki Nakagawa
- Takao MiyagawaTMTakao Miyagawa
- Kazuya SakaiKSKazuya Sakai
- Ryo SajiRSRyo Saji
- Hayato TaniguchiHTHayato Taniguchi
- Kohei TakahashiKTKohei Takahashi
- Takeru AbeTATakeru Abe
- Masayuki IwashitaMIMasayuki Iwashita
Open Access
- 16 August 2021
- journal article
- research article
- Published by Springer Nature in Thrombosis Journal
- Vol. 19 (1) , 1-9
Abstract
Background: Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the endothelial glycocalyx, may be a biomarker of severity classification for COVID-19 related to endothelial injury. Methods and analysis: We analyzed the data of COVID-19 patients for 1 year from February 2020 at Yokohama City University Hospital and Yokohama City University Medical Center Hospital. We selected COVID-19 patients who required admission care, including intensive care, and analyzed the classification of severe and critical COVID-19 retrospectively, using various clinical data and laboratory data with SDC-1 by ELISA. Results: We analyzed clinical and laboratory data with SDC-1 in five severe COVID-19 and ten critical COVID-19 patients. In the two groups, their backgrounds were almost the same. In laboratory data, the LDH, CHE, and CRP levels showed significant differences in each group (P = 0.032, P < 0.0001, and P = 0.007, respectively) with no significant differences in coagulation-related factors (platelet, PT-INR, d-dimer, ISTH score; P = 0.200, 0.277, 0.655, and 0.36, respectively). For the clinical data, the SOFA score was significantly different from admission day to day 14 of admission (p < 0.0001). The SDC-1 levels of critical COVID-19 patients were significantly higher on admission day and all-time course compared with the levels of severe COVID-19 patients (P = 0.009 and P < 0.0001, respectively). Conclusions: Temporal change of SDC-1 levels closely reflect the severity of COVID-19, therefore, SDC-1 may be a therapeutic target and a biomarker for the severity classification of Covid-19.Keywords
All Related Versions
Funding Information
- Yokohama Academic Foundation Grant (771)
This publication has 39 references indexed in Scilit:
- Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patientsJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2019
- Derangement of the endothelial glycocalyx in sepsisJournal of Thrombosis and Haemostasis, 2018
- Interaction between platelets and endothelium: from pathophysiology to new therapeutic optionsCardiovascular Diagnosis and Therapy, 2018
- Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunctionAnnals of Intensive Care, 2017
- Endothelial Glycocalyx Layer Shedding Following Lung ResectionBiomarkers in Medicine, 2016
- Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddasesBritish Journal of Clinical Pharmacology, 2015
- Molecular functions of syndecan-1 in diseaseMatrix Biology, 2012
- Thrombotic risk factors: Basic pathophysiologyCritical Care Medicine, 2010
- Shedding of the Endothelial Glycocalyx in Patients Undergoing Major Vascular Surgery With Global and Regional IschemiaCirculation, 2007
- Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive MetalloproteinaseJournal of Cell Biology, 2000